FrancophonIA/ELRC3.0 huggingface dataset:
English: In a study in virologically suppressed adult patients, improvements in BMD were noted through 96 weeks after switching to Descovy from a TDF containing regimen compared to minimal changes with maintaining the TDF containing regimen as measured by DXA analysis of hip (mean change from baseline of 1.9% vs -0.3%, p < 0.001) and lumbar spine (mean change from baseline of 2.2% vs -0.2%, p < 0.001).
Maltese: Fi studju f'pazjenti adulti b'soppressjoni virali, titjib fil-BMD ġie osservat matul 96 ġimgħa wara li lpazjenti qalbu għal Descovy minn kors li kien fih TDF meta mqabbla ma' tibdil minimu f'dawk li żammew il-kors li kien fih TDF kif imkejjel mill-analiżi DXA tal-ġenbejn (bidla medja mil-linja bażi ta' 1.9% vs -0.3%, p < 0.001) u tas-sinsla lumbari (bidla medja mil-linja bażi ta' 2.2% vs -0.2%, p < 0.001).
English: The recommended dose of Descovy is 200/10 mg once daily.
Maltese: Id-doża rakkomandata ta' Descovy hi ta' 200/10 mg darba kuljum.
English: Ctau
Maltese: JIS
English: In a clinical study of HIV virologically suppressed patients co-infected with chronic hepatitis B, who received emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet (E/C/F/TAF), for 48 weeks (GS-US-292-1249, n = 72), 2 patients qualified for resistance analysis.
Maltese: Fi studju kliniku ta' pazjenti bl-HIV b'soppressjoni virali koinfettati b'epatite B kronika, li rċevew emtricitabine u tenofovir alafenamide, mogħtija flimkien ma' elvitegravir u cobicistat bħala pillola kombinata ta' doża fissa (E/C/F/TAF), għal 48 ġimgħa (GS-US-292-1249, n = 72), 2 pazjenti kkwalifikaw għall-analiżi tar-reżistenza.
English: At Week 48, 81.8% (45/55 patients) maintained HIV-1 RNA < 50 copies/mL after switching to emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet.
Maltese: 8% (45/55 pazjent) żammew l-RNA ta' HIV-1 < 50 kopja/mL wara li qalbu għal emtricitabine u tenofovir alafenamide, mogħtija ma' elvitegravir u cobicistat bħala pillola kkombinata ta' doża fissa.
English: Based on these limited data, the safety profile of emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet, in patients with HIV/HBV co-infection, was similar to that in patients with HIV-1 monoinfection (see section 4.4).
Maltese: Ibbażat fuq din id-data limitata, il-profil tas-sigurtà ta' emtricitabine u tenofovir alafenamide flimkien ma' elvitegravir u cobicistat bħala pillola kombinata ta' doża fissa, f'pazjenti b'koinfezzjoni bl-HIV/HBV, kien simili għal dak f'pazjenti b'monoinfezzjoni bl-HIV-1 (ara sezzjoni 4.4).
English: angioedema3, 4, pruritus, urticaria4 Musculoskeletal and connective tissue disorders Uncommon:
Maltese: anġjoedema3, 4, ħakk, urtikarja4
English: HIV-1 RNA < 20 copies/mL 84.4% Treatment difference
Maltese: HIV-1 RNA < 20 kopja/mL 84.
English: Patients with HIV-1 harbouring mutations
Maltese: Pazjenti infettati b'HIV-1 b'soppressjoni virali
English: The recommended dose of Descovy is 200/25 mg once daily.
Maltese: Id-doża rakkomandata ta' Descovy hi ta' 200/25 mg darba kuljum.
English: Anti-hepatitis C virus medicinal products Ledipasvir (90 mg once daily)/ sofosbuvir (400 mg once daily), emtricitabine (200 mg once daily)/ tenofovir alafenamide (10 mg once daily) 3
Maltese: Prodotti mediċinali kontra l-virus tal-epatite Ċ Ledipasvir (90 mg darba kuljum)/ sofosbuvir (400 mg darba kuljum), emtricitabine (200 mg darba kuljum)/ tenofovir alafenamide (10 mg darba kuljum)3
English: In these 2 patients, no amino acid substitutions associated with resistance to any of the components of E/C/F/TAF were identified in HIV-1 or HBV.
Maltese: F'dawn iż-żewġ pazjenti, ma ġewx identifikati sostituzzjonijiet ta' aċidi amminiċi assoċjati ma' reżistenza għal xi wieħed mill-komponenti ta' E/C/F/TAF f'HIV-1 jew HBV.
English: Tenofovir alafenamide is permeable into cells and due to increased plasma stability and intracellular activation through hydrolysis by cathepsin A, tenofovir alafenamide is more efficient than tenofovir disoproxil fumarate in concentrating tenofovir in peripheral blood mononuclear cells (PBMCs) or HIV target cells including lymphocytes and macrophages.
Maltese: Tenofovir alafenamide hu permeabbli fiċ-ċelluli u minħabba ż-żieda tal-istabbiltà fil-plażma u l-attivazzjoni intraċellulari permezz ta' idrolisi minn cathepsin A, tenofovir alafenamide hu aktar effiċjenti minn tenofovir disoproxil fumarate fil-konċentrazzjoni ta' tenofovir fiċ-ċelluli mononukleari fid-demm periferali (PBMCs) jew fiċ-ċelluli HIV oħrajn fil-mira li jinkludu limfoċiti u makrofaġi.
English: Although kidney problems have not been observed with Descovy, there is a possibility that you may experience kidney problems when taking Descovy over a long period of time.
Maltese: Għalkemm ma ġewx osservati problemi fil-kliewi b'Descovy, hemm possibbiltà li jista' jkollok problemi fil-kliewi meta tieħu Descovy fuq perjodu twil ta' żmien.
English: Following administration of food in healthy subjects, peak plasma concentrations were observed approximately 1 hour post-dose for tenofovir alafenamide administered as F/TAF (25 mg) or E/C/F/TAF (10 mg).
Maltese: Wara l-għoti tal-ikel f'individwi b'saħħithom, il-konċentrazzjonijiet massimi fil-plażma ġew osservati madwar siegħa wara d-doża għal tenofovir alafenamide mogħti bħala F/TAF (25 mg) jew E/C/F/TAF (10 mg).
English: PI = protease inhibitor a Week 48 window was between Day 294 and 377 (inclusive).
Maltese: PI = inibituri tal-protease a L-intervall ta' żmien tal-Ġimgħa 48 kien bejn Jum 294
English: No clinically relevant differences in tenofovir alafenamide, or tenofovir pharmacokinetics were observed between healthy subjects and patients with severe renal impairment (estimated CrCl > 15 mL/min and < 30 mL/min) in a Phase 1 study of tenofovir alafenamide.
Maltese: L-ebda differenzi klinikament rilevanti fil-farmakokinetika ta' tenofovir alafenamide, jew tenofovir ma ġew osservati bejn individwi b'saħħithom u f'pazjenti b'indeboliment renali sever (CrCl stmata ta' ≥ 15-il mL/min u < 30 mL/min) fi studju ta' Fażi 1 ta' tenofovir alafenamide.
English: A minimal infiltration of histiocytes was present in the eye in dogs at tenofovir alafenamide and tenofovir exposures of approximately 4 and 17 times greater, respectively, than those expected after administration of Descovy.
Maltese: Infiltrazzjoni minimali ta' istjoċiti kienet preżenti fl-għajnejn tal-klieb f'esponimenti ta' tenofovir alafenamide u tenofovir ta' madwar 4 u 17-il darba ikbar, rispettivament, minn dawn mistennija wara l-għoti ta' Descovy.
English: 1 With the exception of angioedema, anaemia and urticaria (see footnotes 2, 3 and 4), all adverse reactions were identified from clinical studies of F/TAF containing products.
Maltese: 1 Bl-eċċezzjoni ta' anġjoedema, anemija u urtikarja (ara n-noti 2, 3 u 4 tal-qiegħ), ir-reazzjonijiet avversi kollha ġew identifikati minn studji kliniċi ta' prodotti li fihom F/TAF.
English: In open-label Study GS-US-292-1249, the efficacy and safety of emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet (E/C/F/TAF), were evaluated in adult patients co-infected with HIV-1 and chronic hepatitis B. Sixty-nine of the 72 patients were on prior TDF-containing antiretroviral therapy.
Maltese: Fl-Istudju open-label GS-US-292-1249, l-effikaċja u s-sigurtà ta' emtricitabine u tenofovir alafenamide, mogħtija flimkien ma' elvitegravir u cobicistat bħala pillola kombinata ta' doża fissa (E/C/F/TAF), kienu evalwati f'pazjenti adulti koinfettati b'HIV-1 u epatite B kronika.
English: The pharmacokinetics of emtricitabine and tenofovir alafenamide have not been fully evaluated in patients co-infected with HBV and/or HCV.
Maltese: Il-farmakokinetika ta' emtricitabine u tenofovir alafenamide ma ġietx evalwata b'mod sħiħ f'pazjenti ko-infettati b'HBV u/jew HCV.
English: Ninety-two percent (66/72 patients) had HBV DNA < 29 IU/mL using missing = failure analysis at Week 48.
Maltese: Tnejn u disgħin fil-mija (66/72 pazjent) kellhom DNA ta' HBV <29 IU/mL bl-użu ta' analiżi ta' nieqsa = falliment f'Ġimgħa 48.
English: Descovy film-coated tablets are grey, rectangular-shaped tablets, debossed on one side with “GSI” and the number “210” on the other side of the tablet.
Maltese: Descovy pilloli miksija b'rita huma griżi, b'forma rettangolari, b'“GSI” imnaqqxa fuq naħa waħda u n-numru “210” fuq in-naħa l-oħra tal-pillola.
English: The mean increase from baseline in CD4+ cell count at Week 48 was 224 cells/mm3.
Maltese: Iż-żieda medja mil-linja bażi flgħadd ta' ċelluli CD4+ f'Ġimgħa 48 kien ta' 224 ċellula/mm3.
English: Rash
Maltese: raxx
English: Of the 62 patients who were HBV suppressed at baseline, 59 remained suppressed and
Maltese: Mit-62 pazjent b'soppressjoni ta' HBV fil-linja bażi, 59 baqgħu soppressi u 3 kellhom data nieqsa.
English: nausea
Maltese: UŻU
English: Clinical efficacy of Descovy was established from studies conducted with emtricitabine and tenofovir alafenamide when given with elvitegravir and cobicistat as the fixed-dose combination tablet E/C/F/TAF.
Maltese: L-effikaċja klinika ta' Descovy, ġiet stabbilita minn studji li saru b'emtricitabine u tenofovir alafenamide meta ngħataw ma' elvitegravir u cobicistat bħala l-pillola kombinata ta' doża fissa E/C/F/TAF.
English: In Study GS-US-292-1825, the efficacy and safety of emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet were evaluated in a single arm, open-label clinical study in which 55 HIV-1 infected adults with end stage renal disease (eGFRCG < 15 mL/min) on chronic haemodialysis for at least 6 months before switching to emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet.
Maltese: Fi Studju GS-US-292-1825, l-effikaċja u s-sigurtà ta' emtricitabine u tenofovir alafenamide, mogħtija ma' elvitegravir u cobicistat bħala pillola kkombinata ta 'doża fissa kienu evalwati fi studju kliniku, open-label, bi grupp wieħed li fih 55 adult infettati bl-HIV-1 b'marda tal-kliewi fl-aħħar stadju (eGFRCG < 15-il mL/min) fuq emodijalisi kronika għal mill-inqas 6 xhur qabel ma qalbu għal emtricitabine u tenofovir alafenamide, mogħtija flimkien ma' elvitegravir u cobicistat bħala pillola kkombinata ta' doża fissa.
English: Descovy should be avoided in patients with estimated CrCl ≥ 15 mL/min and < 30 mL/min, or < 15 mL/min who are not on chronic haemodialysis, as the safety of Descovy has not been established in these populations.
Maltese: Descovy għandu jiġi evitat f'pazjenti b'CrCl stmata ta' ≥ 15-il mL/min u < 30 mL/min, jew < 15-il mL/min li mhumiex fuq emodijalisi kronika, peress li s-sigurtà ta' Descovy ma ġietx stabbilita f'dawn il-popolazzjonijiet.
English: Missing data during window but on study drug Proportion (%) of patients with HIV-1 RNA < 50 copies/mL by subgroup Age
Maltese: Proporzjon (%) ta' pazjenti b'HIV-1 RNA ta' < 50 kopja/mL skont issottogrupp
English: The safety and efficacy of Descovy in patients with significant underlying liver disorders have not been established (see sections 4.2 and 5.2).
Maltese: Is-sigurtà u l-effikaċja ta' Descovy f'pazjenti b'disturbi tal-fwied sottostanti sinifikanti ma ġewx stabbiliti (ara sezzjonijiet 4.2 u 5.2).
English: Ledipasvir (90 mg once daily)/ sofosbuvir (400 mg once daily), emtricitabine (200 mg once daily)/ tenofovir alafenamide (25 mg once daily)4
Maltese: Ledipasvir (90 mg darba kuljum)/ sofosbuvir (400 mg darba kuljum), emtricitabine (200 mg darba kuljum)/ tenofovir alafenamide (25 mg darba kuljum)4
English: The pharmacokinetics of emtricitabine have not been studied in subjects with hepatic impairment; however, emtricitabine is not significantly metabolised by liver enzymes, so the impact of liver impairment should be limited.
Maltese: Il-farmakokinetiċi ta' emtricitabine ma ġewx studjati f'individwi b'indeboliment epatiku; madankollu, emtricitabine ma jiġix metabolizzat b'mod sinifikanti mill-enzimi tal-fwied, u għalhekk l-impatt ta' indeboliment epatiku għandu jkun limitat.
English: Seventy-nine percent were male, 63% were White, 18% were Black, and 14% were Asian.
Maltese: Disa' u sebgħin fil-mija kienu rġiel, 63% kienu Bojod, 18% kienu Suwed, u 14% kienu Asjatiċi.
English: Dose Descovy according to the concomitant antiretroviral (see section 4.2).
Maltese: Agħti d-doża ta' Descovy skont l-antiretrovirali li jingħata flistess ħin (ara sezzjoni 4.2).
English: The safety of emtricitabine and tenofovir alafenamide was evaluated through 48 weeks in a single arm, open-label clinical study (GS-US-292-1825) in which 55 virologically suppressed HIV-1 infected patients with end stage renal disease (eGFRCG < 15 mL/min) on chronic haemodialysis received emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet.
Maltese: Is-sigurtà ta' emtricitabine u tenofovir alafenamide kienet evalwata sa 48 ġimgħa fi studju kliniku (GS-US-292-1825) open label, bi grupp wieħed li fih 55 pazjent infettati bl-HIV-1 soppressi b'mod viroloġiku u b'marda tal-kliewi fl-aħħar stadju (eGFRCG < 15-il mL/min) fuq emodijalisi kronika rċivew emtricitabine u tenofovir alafenamide flimkien ma' elvitegravir u cobicistat bħala pillola kkombinata ta' doża fissa.
English: No antagonism was observed with emtricitabine or tenofovir alafenamide when combined with other antiretroviral agents.
Maltese: Ma ġie osservat l-ebda antagoniżmu ma' emtricitabine jew tenofovir alafenamide meta ġew ikkombinati ma' mediċini antiretrovirali oħrajn.
English: At Week 48, 92% of patients (66/72) maintained HIV-1 RNA < 50 copies/mL after switching to emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet.
Maltese: F'Ġimgħa 48, 92% tal-pazjenti (66/72) żammew RNA ta' HIV-1 < 50 kopja/mL wara li qalbu għal emtricitabine u tenofovir alafenamide, mogħtija ma' elvitegravir u cobicistat bħala pillola kombinata ta' doża fissa.
English: Darunavir/ritonavir (800/100 mg once daily), tenofovir alafenamide (10 mg once daily)
Maltese: Darunavir/ritonavir (800/100 mg darba kuljum), tenofovir alafenamide (10 mg darba kuljum)
English: In Study GS-US-311-1717, patients who were virologically suppressed (HIV-1 RNA <50 copies/mL) on their abacavir/lamivudine containing regimen for at least 6 months were randomised in a 1:1 ratio to either switch to Descovy (N=280) while maintaining their third agent at baseline or stay on their baseline abacavir/lamivudine -containing regimen (N=276).
Maltese: Fi Studju GS-US-311-1717, il-pazjenti b'soppressjoni virali (HIV-1 RNA <50 kopja/mL) fuq il-kors tagħhom li kien fih abacavir/lamivudine għal mill-inqas 6 xhur intgħażlu b'mod randomised fi proporzjon ta' 1:1 biex jew jaqilbu għal Descovy (N=280) filwaqt li tinżamm it-tielet sustanza tagħhom fil-linja bażi jew jibqgħu fuq il-kors tagħhom fil-linja bażi li kien fih abacavir/lamivudine (N=276).
English: In studies in treatment-naïve patients, emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat as a fixed-dose combination tablet through 144 weeks was associated with a lower impact on renal safety parameters (as measured after 144 weeks treatment by eGFRCG and urine protein to creatinine ratio and after 96 weeks treatment by urine albumin to creatinine ratio) compared to E/C/F/TDF.
Maltese: Fi studji f'pazjenti li qatt ma ngħataw trattament fil-passat, emtricitabine u tenofovir alafenamide mogħtija ma' elvitegravir u cobicistat bħala pillola kombinata ta' doża fissa matul 144 ġimgħa ġew assoċjati ma' impatt iżgħar fuq il-parametri tas-sigurtà renali (kif imkejla wara 144 ġimgħa ta' trattament minn eGFRCG u l-proporzjon ta' proteina fl-awrina mal-kreatinina u wara 96 ġimgħa ta' trattament mill-proporzjon ta' albumina fl-awrina mal-kreatinina) meta mqabbla ma' E/C/F/TDF.
English: Exposures of emtricitabine and tenofovir in 12 patients with end stage renal disease (estimated CrCl < 15 mL/min) on chronic haemodialysis who received emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet (E/C/F/TAF) in Study GS-US-292-1825 were significantly higher than in patients with normal renal function.
Maltese: Esponimenti għal emtricitabine u tenofovir fi 12-il pazjent b'marda tal-kliewi fl-aħħar stadju (CrCl stmata ta' < 15-il mL/min) fuq emodijalisi kronika li rċivew emtricitabine u tenofovir alafenamide flimkien ma' elvitegravir u cobicistat bħala pillola kkombinata ta' doża fissa (E/C/F/TAF) fl-Istudju GS-US-292-1825 kienu sinifikament ogħla milli f'pazjenti b'funzjoni renali normali.
English: In a separate study, emtricitabine and tenofovir alafenamide given with darunavir and cobicistat as a fixed-dose combination tablet was also associated with smaller reductions in BMD (as measured by hip and lumbar spine DXA analysis) through 48 weeks of treatment compared to darunavir, cobicistat, emtricitabine and tenofovir disoproxil fumarate.
Maltese: Fi studju separat, emtricitabine u tenofovir alafenamide mogħtija ma' darunavir u cobicistat bħala pillola kombinata ta' doża fissa ġew assoċjati wkoll ma' tnaqqis iżgħar filBMD (kif imkejla permezz ta' analiżi DXA tal-ġenbejn u tas-sinsla lumbari) matul 48 ġimgħa ta' trattament meta mqabbla ma' darunavir, cobicistat, emtricitabine u tenofovir disoproxil fumarate.
English: Co-administration of Descovy with other medicinal products that inhibit P-gp and BCRP activity (e.g., cobicistat, ritonavir, ciclosporin) is expected to increase the absorption and plasma concentration of tenofovir alafenamide.
Maltese: L-għoti flimkien ta' Descovy ma' prodotti mediċinali oħrajn li jinibixxu l-attività ta' P-gp u ta' BCRP (eż., cobicistat, ritonavir, ciclosporin) huwa mistenni li jżid l-assorbiment u l-konċentrazzjoni ta' tenofovir alafenamide filplażma.
English: Third agent in HIV treatment regimen (see section 4.5)
Maltese: It-tielet mediċina fil-kors ta' kura kontra l-HIV (ara sezzjoni 4.5)
English: How to take Descovy
Maltese: X'fih Descovy
English: Descovy 200 mg/10 mg film-coated tablets
Maltese: Descovy 200 mg/10 mg pilloli miksija b'rita
English: Medicinal product by therapeutic areas1
Maltese: Prodott mediċinali skont iżżoni terapewtiċi1
English: At baseline, 30% of patients were receiving abacavir/lamivudine in combination with a boosted protease inhibitor and 70% of patients were receiving abacavir/lamivudine in combination with an unboosted third agent.
Maltese: Fil-linja bażi, 30% tal-pazjenti kienu qed jirċievu abacavir/lamivudine flimkien ma' inibitur ta' protease msaħħaħ u 70% tal-pazjenti kienu qed jirċievu abacavir/lamivudine flimkien ma' tielet sustanza mhux imsaħħa.
English: D/C/F/TAF (n = 103)
Maltese: D/C/F/TAF
English: In a pooled analysis of antiretroviral-naïve patients receiving emtricitabine and tenofovir alafenamide (10 mg) given with elvitegravir and cobicistat as a fixed-dose combination tablet in Phase 3 studies GS-US-292-0104 and GS-US-292-0111, genotyping was performed on plasma HIV-1 isolates from all patients with HIV-1 RNA ≥ 400 copies/mL at confirmed virological failure, at Week 144, or at the time of early study drug discontinuation.
Maltese: F'analiżi miġbura ta' pazjenti li qatt ma' kienu ngħataw mediċini antiretrovirali qabel, li kienu qed jirċievu emtricitabine u tenofovir alafenamide (10 mg) mogħtija ma' elvitegravir u cobicistat bħala pillola kombinata ta' doża fissa fi studji ta' Fażi 3 GS-US-292-0104 u GS-US-292-0111, twettaq ġenotipar fuq iżolati ta' HIV-1 mill-pazjenti kollha b'HIV-1 RNA ta' ≥ 400 kopja/mL meta kellhom falliment viroloġiku kkonfermat, f'Ġimgħa 144, jew meta seħħ it-twaqqif bikri tal-mediċina tal-istudju.
English: Atazanavir with ritonavir or cobicistat Darunavir with ritonavir or cobicistat1 Lopinavir with ritonavir
Maltese: Il-mediċina tal-istudju twaqqfet minħabba raġunijiet oħrajn u laħħar HIV-1 RNA < 50 kopja/mL disponibblie
English: The safety of emtricitabine and tenofovir alafenamide was evaluated through 48 weeks in an openlabel clinical study (GS-US-292-0106) in which HIV-1 infected, treatment-naïve paediatric patients aged 12 to < 18 years received emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet.
Maltese: Is-sigurtà ta' emtricitabine u tenofovir alafenamide ġiet evalwata sa 48 ġimgħa fi studju kliniku openlabel (GS-US-292-0106) f'pazjenti pedjatriċi infettati bl-HIV-1, li qatt ma ngħataw trattament filpassat, u li kellhom minn 12 sa < 18-il sena rċivew emtricitabine u tenofovir alafenamide flimkien ma' elvitegravir u cobicistat bħala pillola kombinata ta' doża fissa.
English: Co-administration of St. John's wort, a P-gp inducer, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Maltese: John's wort, induttur ta' P-gp, jista' jnaqqas ilkonċentrazzjonijiet ta' tenofovir alafenamide fil-plażma, li jista' jirriżulta fit-telf tal-effett terapewtiku u l-iżvilupp ta' reżistenza.
English: Nephrotoxicity
Maltese: Phenytoin
English: Emtricitabine: AUC: ↔
Maltese: AUC: ↔
English: Sofosbuvir (400 mg once daily)/ velpatasvir (100 mg once daily), emtricitabine (200 mg once daily)/ tenofovir alafenamide (10 mg once daily)3
Maltese: Sofosbuvir (400 mg darba kuljum)/ velpatasvir (100 mg darba kuljum), emtricitabine (200 mg darba kuljum)/ tenofovir alafenamide
English: 0.007 to 0.075 μM) and showed strain specific activity against HIV-2 (EC50 values ranged from 0.007
Maltese: HIV-2 (il-figuri ta' EC50 kienu jvarjaw minn 0.007 sa 1.5 µM).
English: 4 Study conducted with emtricitabine/rilpivirine/tenofovir alafenamide fixed-dose combination tablet.
Maltese: 6 Emtricitabine/tenofovir alafenamide ittieħed mal-ikel f'dan l-istudju.
English: 5 Study conducted with Descovy.
Maltese: Mediċini oħra u Descovy
English: AUC: ↑ 48% Cmax: ↔ Cmin: ↑ 66%
Maltese: AUC: ↔ Cmin: ↑ 46% Cmax: ↔
English: ANTI-INFECTIVES Antifungals Ketoconazole Itraconazole
Maltese: Disturbi muskolu-skeletriċi u tat-tessuti konnettivi
English: Each Descovy film-coated tablet contains 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide.
Maltese: Kull pillola miksija b'rita ta' Descovy fiha 200 mg ta' emtricitabine u tenofovir alafenamide fumarate, ekwivalenti għal 10 mg ta' tenofovir alafenamide.
English: Each Descovy film-coated tablet contains 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide.
Maltese: Kull pillola miksija b'rita ta' Descovy fiha 200 mg ta' emtricitabine u tenofovir alafenamide fumarate, ekwivalenti għal 25 mg ta' tenofovir alafenamide.
English: The safety and efficacy of Descovy in patients co-infected with HIV-1 and hepatitis C virus (HCV) have not been established.
Maltese: Is-sigurtà u l-effikaċja ta' Descovy f'pazjenti ko-infettati bl-HIV-1 u bil-virus tal-epatite Ċ (HCV) ma ġewx stabbiliti.
English: • antibiotics, used to treat bacterial infections including tuberculosis, containing:
Maltese: • antibijotiċi, li jintużaw għal trattament ta' infezzjonijiet batteriċi li jinkludu t-tuberkulożi, li fihom:
English: Patients were randomised in a 1:1 ratio to either switch to Descovy (n = 333), or stay on their baseline emtricitabine/tenofovir disoproxil fumarate containing regimen (n = 330).
Maltese: Il-pazjenti ntgħażlu b'mod randomised fi proporzjon ta' 1:1 biex jew jaqilbu għal Descovy (n = 333), jew jibqgħu fuq il-kors tagħhom fil-linja bażi li kien fih emtricitabine/tenofovir disoproxil fumarate (n = 330).
English: In studies GS-US-292-0104 and GS-US-292-0111, patients were randomised in a 1:1 ratio to receive either emtricitabine 200 mg and tenofovir alafenamide 10 mg (n = 866) once daily or emtricitabine
Maltese: GS-US-292-0104 u GS-US-292-0111, il-pazjenti ntgħażlu b'mod randomised fi proporzjon ta' 1:1 biex jirċievu jew emtricitabine 200 mg u tenofovir alafenamide 10 mg (n = 866) darba kuljum jew emtricitabine 200 mg + tenofovir disoproxil (bħala fumarate) 245 mg (n = 867) darba kuljum, ittnejn mogħtija ma' elvitegravir 150 mg + cobicistat 150 mg bħala pillola kombinata ta' doża fissa.